MedTrace Logo

Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart Failure and Reduced Ejection Fraction

NCT04141800 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 565

Last updated 2021-05-25

No results posted yet for this study

Summary

* Participant centres and researchers:

20 National Public Health System hospitals. Cardiology specialist physicians
* Clinical Research Ethics Committee (CREC):

Hospital 12 de Octubre, Madrid

\- Main goal: To estimate prevalence and, in medium term basis (12 months), incidence of hyperkalaemia in heart failure (HF) outpatients with reduced ejection fraction (REF) and its relationship with non-optimal HF therapy and clinical outcomes (mortality and hospital admission).

\- Study design: National multicentric prospective observational study that includes 12 months follow-up of consecutive cases of HF outpatients with REF. Inclusion baseline visit and follow -up visits at 12 months will be scheduled for collecting clinical and blood sample data of patients.

\- Study population: The expected number of patients recruited in 20 Spanish research centres is 600.

Conditions

  • Heart Failure With Reduced Ejection Fraction
  • Hyperkalemia

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Spanish Society of Cardiology

    lead OTHER

Principal Investigators

  • María G Crespo Leiro, MD, PhD · Complejo Hospitalario Universitario de A Coruña (CHUAC)

  • Juan Delgado Jiménez, MD, PhD · Hospital Universitario 12 de Octubre, Madrid

  • Javier Muñiz García, MD, PhD · Instituto Universitario de Ciencias da Saúde. Universidade da Coruña. INIBIC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-30
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04141800 on ClinicalTrials.gov